

PHARMACY POLICY STATEMENT

Ohio Medicaid

DRUG NAME	Yescarta (axicabtagene ciloleucel)
BILLING CODE	TBD
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Outpatient/Office
COVERAGE REQUIREMENTS	Prior Authorization Required (Non-Preferred Product) QUANTITY LIMIT – see Dosage allowed below
LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY	Click Here

Yescarta (axicabtagene ciloleucel) is a **non-preferred** product and will only be considered for coverage under the **medical** benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

CAR-T CELL IMMUNOTHERAPY (autologous use only)

For **initial** authorization:

1. Medication is being use for adult member with relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, or DLBCL arising from follicular lymphoma); AND
2. Member has relapsed/refractory transplant ineligible disease, documented in chart notes and defined as **one** or more of the following:
 - a) No response to first (primary refractory disease), second or greater lines of therapy;
 - b) Relapsed after autologous hematopoietic stem cell transplantation (HSCT);
 - c) Relapsed transplant ineligible disease; AND
3. Member must have received adequate prior therapy including at a minimum **both** of the following:
 - a) Anti-CD20 monoclonal antibody (unless tumor is CD20 negative);
 - b) An anthracycline containing chemotherapy regimen; AND
4. Member received the lymphodepleting regimen (cyclophosphamide 500 mg/m² intravenously and fludarabine 30 mg/m² intravenously, both given on the fifth, fourth, and third day before Yescarta); AND
5. Member has been screened for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) prior to collection of cells (leukapheresis); AND
6. Healthcare facility/provider has enrolled in the Yescarta REMS and has training on the management of cytokine release syndrome (CRS) and neurological toxicities; AND
7. Member must be premedicated with acetaminophen and an H1-antihistamine, and tocilizumab (Actemra) must be available in healthcare facility prior to infusion; AND
8. Member does **not** have history of ANY of the following:
 - a) Severe, immediate hypersensitivity reaction attributed to aminoglycosides;
 - b) Prior allogeneic HSCT;
 - c) History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
9. **Dosage allowed:** 2 × 10⁶ CAR-positive viable T cells per kg body weight, with a maximum of 2 × 10⁸ CAR-positive viable T cells.



Note: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

If member meets all the requirements listed above, the medication will be approved for 3 months.

For **reauthorization**:

1. Yescarta will not be reauthorized for continued therapy.

CareSource considers Yescarta (axicabtagene ciloleucel) not medically necessary for the treatment of the diseases that are not listed in this document.

DATE	ACTION/DESCRIPTION
10/24/2017	New policy for Yescarta created.

References:

1. Yescarta [package insert]. Santa Monica, CA; Kite Pharma, Inc., October 2017. Accessed October 2017.
2. The Leukemia & Lymphoma Society (LLS). Ph-Positive ALL Therapy. Available at <https://www.lls.org/leukemia/acute-lymphoblastic-leukemia/treatment/ph-positive-all-therapy>.
3. ClinicalTrials.gov. Identifier NCT03153462. Axicabtagene Ciloleucel Expanded Access Study (ZUMA-9). Available at <https://clinicaltrials.gov/ct2/show/NCT03153462?term=axicabtagene&rank=1>. Accessed in October, 2017.

Effective date: 11/08/2017

Revised date: 10/24/2017